Sophie Gysemberg SRL SRL
Sophie Gysemberg SRL reported total assets of 655,850 € at the end of the 2025 financial year (annual accounts filed with the NBB on 04 Jun 2026).
The score of Sophie Gysemberg SRL shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +58 % Total assets -4 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sophie Gysemberg SRL's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 04 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 17 Jun 2024
- Year ended 31 Dec 2022filed on 12 Jun 2023
- Year ended 31 Dec 2021filed on 31 Jul 2022
Sophie Gysemberg SRL's financial analysis
- Solvency37.7%sector median: 37.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sophie Gysemberg SRL
Sophie Gysemberg SRL's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0745.718.182
- VAT number
- BE0745718182
- Peppol
- Registered · 0208:0745718182 · as of 11 Nov 2026
- Legal form
- SRL
- Incorporated
- 31 Mar 2020
- Registered office
- 1160 Auderghem
- Latest accounts
- 2025 · filed on 04 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Sophie Gysemberg SRL (SRL) has been based in Auderghem since 2020, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 31,203 € and equity of 247,076 €; its revenue is not published. Its solvency stands at 37.7%, above the median of its sector (37.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Sophie Gysemberg SRL
Companies in the same business, of comparable size and area, outside its group.
- ANAP Retail sale of pharmaceutical products Aalst · balance sheet €1.37m
- Lena Malcorps Retail sale of pharmaceutical products Sint-Truiden · balance sheet 704,130 €
- Cosmephar Retail sale of pharmaceutical products Antwerp · balance sheet 561,007 €
- VRB Farma Retail sale of pharmaceutical products Mechelen · balance sheet 551,620 €
- Apotheek het Perron Retail sale of pharmaceutical products Poperinge · balance sheet 862,885 €
- Pharmacie de la Place de Ghlin Retail sale of pharmaceutical products Frameries · balance sheet 814,548 €
- Mylle Pharma Retail sale of pharmaceutical products Anzegem · balance sheet 947,525 €
- Rozental & Herman Retail sale of pharmaceutical products Charleroi · balance sheet €1.05m
Frequently asked questions about Sophie Gysemberg SRL
What is the revenue of Sophie Gysemberg SRL?
Sophie Gysemberg SRL files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Sophie Gysemberg SRL?
In Belgium, the VAT number is the company number prefixed with BE: BE0745718182 for Sophie Gysemberg SRL, if the company is VAT-registered. Its company number (CBE) is 0745.718.182.
Where is the registered office of Sophie Gysemberg SRL?
According to the CBE register, the registered office of Sophie Gysemberg SRL is in 1160 Auderghem.
What is the equity of Sophie Gysemberg SRL?
At the close of the 2025 financial year, the equity of Sophie Gysemberg SRL amounts to 247,076 €, a solvency of 37.7% of total assets.
Who manages Sophie Gysemberg SRL?
The register lists 1 active mandates at Sophie Gysemberg SRL. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sophie Gysemberg SRL
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →